Dr Rachel Popelka-Filcoff, an Australian Institute of Nuclear Science and Engineering (AINSE) Senior Research Fellow; image courtesy of Flinders University


The first non-destructive analysis of Australian Aboriginal ochre artefacts using advanced X-Ray technology has paved the way for more accurate cultural mapping and new insights into the origin and style of Indigenous artworks.  


While European-style artworks have been analysed using X-Ray Fluorescence Microscopy (XFM) techniques, the new research kickstarts ‘hands off’ high-tech analysis of Aboriginal Australian art, beginning with a boomerang and a bark painting from the South Australian Museum's Australian Aboriginal Culture Collection.


Lead researcher Dr Rachel Popelka-Filcoff from Flinders University says the sensitive analysis of ochre-decorated objects using the XFM beamline at the Australian Synchrotron will help researchers better understand the cultural uses and techniques of Indigenous art and artefacts.


‘Relatively little is understood about the procurement, composition, and mixing of the natural mineral pigments that have been used in Aboriginal Australian objects. 


‘This new method provides higher resolution information and an alternative to traditional destructive testing, while returning the object unharmed to the museum collection.’


In Indigenous communities, from human habitation of Australia to contemporary communities, ochres of many colours are used with wood and bark for cultural expression and exchange of ideas and knowledge.


Dr Popelka-Filcoff, an Australian Institute of Nuclear Science and Engineering (AINSE) Senior Research Fellow who has previously analysed more than 150 different kinds of ochre used around Australia, says high-resolution maps of pigment application generated at the Australian Synchrotron investigate the layering and application of ochre minerals without physically removing samples from the object.


‘Investigating the fine lines and dots in many Aboriginal objects, this technique has unparalleled resolution over other existing techniques, allowing further insights into the composition, application and layering of natural pigment on the micron scale.


‘The findings from across Australia will help to reconstruct ancient exchange routes, build on the existing provenance of Aboriginal art and objects, and help conservation and authentication studies.’


Dr David Paterson, Principal Scientist on the X-ray fluorescence microprobe at the Australian Synchrotron says the use of a highly sensitive and very efficient X-ray detector allows the radiation dose, particularly on these very old objects, to be as low as possible.


‘By using the powerful X-ray fluorescence microprobe for this research experts could gain more accurate data on the composition of the mineral pigments, much faster than other traditional X-ray methods, without damaging the ochre.’


The findings, also involving researchers from the University of South Australia, were published in Royal Society of Chemistry's Analyst journal and latest Emerging Investigators issue.  


Media coverage:


Researchers are one step closer to creating a universal, one-shot influenza vaccine following the discovery that T cells, essential in the immune response to influenza, can recognise and attack emerging, mutant strains of the virus.


An international research collaboration, led by University of Melbourne Associate Professor Katherine Kedzierska from the Peter Doherty Institute for Infection and Immunity and Dr Stephanie Gras from Monash University, used cutting edge single-cell technology, never before used in human influenza investigations, to hone in on human T cells one cell at a time to capture their response to the various strains.


The study, published in Proceedings of the National Academy of Sciences (PNAS) on Monday, found how the T cells reacted to new mutant strains of influenza as well as viruses they had previously been exposed to.


The team used the Australian Synchrotron to scrutinise the structure of the cells to identify how they recognise the mutant strains. They found that it was their flexibility and ability to adapt that enabled the T cells to essentially bully the new strains into submission.


Associate Professor Kedzierska said finding this piece of the puzzle was a major step forward on the path to creating a one-shot, T cell-mediated influenza vaccine for life-long immunity against the virus, which the World Health Organization estimates infects between three and five million people globally every year.


‘This is a game changer in flu research. Previous research has shown us T cells provide universal, protective immunity to influenza but, until now, we didn’t know why or how.


‘By using state-of-the-art procedures, this study enabled us to dissect the immune response to understand how this immunity occurs.’


Associate Professor Kedzierska said further research was necessary before a universal vaccine could be created.


‘Our past research has shown that only a seventh of the world’s population have the tissue make-up that provides universal immunity to influenza, the difference between a runny nose and being bed ridden.


‘Now we know what to look for, our challenge is to find these receptors in those with a different tissue composition and elicit a similar response.’


Dr Stephanie Gras said the precise, high-power X-Ray capability of the Macromolecular and Micro Crystallography (MX1 and MX2) beamlines was essential to the four-year study.


‘Use of the Australian Synchrotron was absolutely crucial to understanding these fine details of the immune response to influenza.’


Above image courtesy of ABC news


Media coverage:


On Wednesday 9 March, the Minister for Industry, Innovation and Science, the Hon. Christopher Pyne MP, visited the Australian Synchrotron, touring the facility floor before announcing the Australian Government's agreement to the facility’s transfer to the Australian Nuclear Science and Technology Organisation (ANSTO).

While visiting the Micro Crystallography (MX2) beamline Mr Pyne was updated on a new anti-leukaemia drug developed in Australia thanks to the combination of a world-class medical research institute, the best and brightest researchers and access to the Australian Synchrotron’s landmark infrastructure, and partnership with industry, ensuring  Australian public hospital patients were the first in the world to access this novel therapy.